FindTrial
Sign In

Citicoline as Neuroprotector in Neonates Exposed to Hypoxia

Efficacy of Citicoline as Neuroprotector in Neonates Exposed to Hypoxia: A Randomized Controlled Trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03949049
Enrollment
40
Registered
2019-05-14
Start date
2019-02-01
Completion date
2029-12-01
Last updated
2019-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal Hypoxia

Brief summary

Citicoline as neuroprotector in neonates exposed to hypoxia: A randomized controlled trial

Detailed description

Efficacy of Citicoline as neuroprotector in neonates exposed to hypoxia: A randomized controlled trial

Interventions

DRUGCiticoline

Citacoline as neuroprotector

OTHERPlacebo

placebo group

Sponsors

Sherief Abd-Elsalam
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
No minimum to 1 Months
Healthy volunteers
No

Inclusion criteria

* neonates with hypoxia.

Exclusion criteria

* hypoxic ischemic encephalopathy

Design outcomes

Primary

MeasureTime frame
number of seizures6 months

Countries

Egypt

Contacts

Primary Contactsherief abd-elsalam, ass. prof.
sheriefabdelsalam@yahoo.com00201147773440

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026